Last edition
News about "clinical trial "
Caliway Reports Positive Phase 2 Results in Dercum's Disease
Caliway Biopharmaceuticals has reported final Phase 2 results showing sustained pain reduction with CBL-514 in patients with Dercum’s disease.
Clinical Trial | 24/09/2026 | By News Bureau
Tangram Therapeutics Advances TGM-312 into MASH Patient Cohorts in Phase 1/2 Trial
Tangram Therapeutics advances TGM-312 into MASH patient cohorts in its Phase 1/2 RESTORE-MASH trial while appointing Dr Sonya Montgomery as Chief Development Officer to drive its clinical pipeline.
Clinical Trial | 05/09/2026 | By News Bureau
Akeso's B7-H3 ADC AK157D1 Cleared for Phase I Clinical Trial in China
Akeso has received NMPA clinical trial clearance for AK157D1, a next-generation B7-H3-targeting ADC, paving the way for a Phase I study in patients with advanced solid tumours in China.
Clinical Trial | 24/08/2026 | By News Bureau | 123
Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer
Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.
Clinical Trial | 10/08/2026 | By News Bureau | 173
World-First Fridge-Free Tetanus-Diphtheria Vaccine Trial Shows Promising Results
Stablepharma’s SPVX02 remains potent for up to two years at temperatures of up to 30°C, potentially reducing cold-chain dependence, vaccine wastage and barriers to immunisation in remote regions.
Clinical Trial | 10/08/2026 | By News Bureau
4Moving Biotech has completed patient enrollment in its global Phase 2a INFLAM MOTION trial, assessing the safety and efficacy of investigational therapy 4P004 for inflammatory knee osteoarthritis.
Clinical Trial | 05/08/2026 | By News Bureau | 1431
GlycoNex Doses First Patient in Phase 1 Trial of GNX1021
GlycoNex dosed the first patient in its phase 1 trial of GNX1021, advancing its glycan-directed Antibody Drug Conjugate (ADC) while exploring global licensing and co-development deals.
Clinical Trial | 03/08/2026 | By News Bureau
ProMIS Neurosciences Reports Positive Interim Phase 1b Results for Alzheimer's Therapy PMN310
ProMIS Neurosciences has reported positive six-month interim data from its Phase 1b PRECISE-AD trial, with PMN310 demonstrating a favourable safety profile, no ARIA-E cases and encouraging biomarker trends in patients with Alzheimer's disease.
Clinical Trial | 30/07/2026 | By News Bureau | 192
Sanofi to not Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews
Sanofi will not seek global regulatory approval for amlitelimab in Atopic Dermatitis (AD) after efficacy and safety data did not support further development.
Clinical Trial | 27/07/2026 | By News Bureau | 164
Healx Doses First Patient in Phase 1/2 Trial of AI-Discovered Therapy for Relapsed Osteosarcoma
Healx has dosed the first patient in its Phase 1/2 trial of AI-developed investigational therapy HLX-4310, marking a milestone in the development of novel treatments aimed at preventing metastatic recurrence in osteosarcoma and other rare cancers.
Clinical Trial | 24/07/2026 | By News Bureau | 154
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy